time to treatment failure


Also found in: Acronyms.

time to treatment failure

, time-to-treatment failure,

TTF

In cancer care, the number of months after the disease is treated before the cancer spreads and the patient's health worsens.
References in periodicals archive ?
The primary outcome was time to treatment failure, a novel composite endpoint of any of three events: the need for treatment intensification, the need for step-up hospital care (either ICU admission or hospital readmission), or death by any cause.
Median time to treatment failure was 226 days in the oral antipsychotic group and nearly twice as long at 416 days in the injectable paliperidone palmitate group.
The company reported orBec did not achieve statistical significance in its primary endpoint of time to treatment failure through day 50 compared to placebo but did achieve statistical significance in the secondary endpoint, time to treatment failure through day 80 compared to placebo.
Approval of efavirenz was based on 2 clinical trials in which the response was measured as time to treatment failure. Study 006 is an ongoing, randomized, open-label trial comparing efavirenz/ indinavir (Crixivan) against efavirenz/zidovudine (Retrovir)/lamivudine (Epivir) against indinavir/ zidovudine/lamivudine.
MELANOMA PATIENTS who took high doses of glucocorticoids for hypophysitis induced by the checkpoint-inhibitor ipilimumab (Yervoy) had a lower overall survival time and a shorter time to treatment failure than did patients taking low-dose steroids for the adverse event, according to a new retrospective analysis in Cancer.
Superiority in progression-free survival and time to treatment failure was demonstrated with second-generation EGFR-directed therapy afatinib, versus first-generation gefitinib in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with common EGFR mutations (del19 or L858R).
The PRIDE trial looked at time to treatment failure in 444 schizophrenia patients over 15 months--226 were treated with IM paliperidone (Invega Sustenna) and 218 were treated with one of seven oral antipsychotics (aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, or risperidone).
El-Nashar reported that there were no significant differences in the time to treatment failure between the two groups, with a 3-year cumulative failure rate of 9% in the RFA group, compared with 12% in the TBA group.
The primary outcome was time to treatment failure, strictly defined as failure to enter prednisone-free remission at week 14 and failure to maintain remission through week 50.
Median time to treatment failure was 9.9 months in the vaccine group, with 13 of 21 patients showing decreases in PSA velocity.
The results indicate that no effect has been observed for either the primary endpoint, overall survival (OS), or for any of the secondary endpoints (progression-free survival PFS , time to progression TTP and time to treatment failure).
The trial's primary outcome was time to treatment failure, which the investigators defined in seven ways, including physician judgment.